CLEANSPACE HOLDINGS LIMITED (CSX)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
![](/stocklogo/CSX.jpg)
CSX - CLEANSPACE HOLDINGS LIMITED
FNArena Sector :
Medical Equipment & Devices
Year End: June
GICS Industry Group : No Sector
Debt/EBITDA: -0.29
Index:
FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : No Sector
Debt/EBITDA: -0.29
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.37
25 Jul |
OPEN $0.42 |
HIGH $0.42 |
30,029 LOW $0.36 |
OTHER COMPANIES IN THE SAME SECTOR | |||
4DX . AT1 . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI . |
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | -10.6 |
DPS All | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | 12.1 M |
Book Value Per Share | xxx | xxx | xxx | xxx | 28.5 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | -12.0 M |
Net Profit Margin | xxx | xxx | xxx | xxx | -67.24 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | -31.45 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | -28.92 % |
Return on Assets | xxx | xxx | xxx | xxx | -24.15 % |
Return on Equity | xxx | xxx | xxx | xxx | -31.45 % |
Return on Total Capital | xxx | xxx | xxx | xxx | -39.61 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | -12.0 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | 1 M |
Long Term Debt | xxx | xxx | xxx | xxx | 3 M |
Total Debt | xxx | xxx | xxx | xxx | 4 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | - |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | 12 M |
Price To Book Value | xxx | xxx | xxx | xxx | 0.70 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | 0.0 M |
Capex % of Sales | xxx | xxx | xxx | xxx | 0.04 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | 17 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | 7 M |
Research & Development | xxx | xxx | xxx | xxx | 1 M |
Investments - Total | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
CSX STOCK CHART
![](/wp-content/uploads/2020/10/img-side-banner-stock-analysis.jpg)
FNArena News on CSX
Latest Medical Equipment & Devices News
1 |
Dr Boreham’s Crucible: BlinklabMay 20 2024 - Small Caps |
2 |
ResMed Silences The DoubtersApr 29 2024 - Australia |
3 |
Dr Boreham’s Crucible: 4D MedicalApr 23 2024 - Small Caps |
4 |
Uptrend Resumed For ResMedMar 19 2024 - Technicals |
5 |
Dr Boreham’s Crucible: CochlearFeb 28 2024 - Australia |
6 |
Rudi Interviewed: Ongoing Potential In Technology & GrowthFeb 19 2024 - Rudi's View |
7 |
Dr Boreham’s Crucible: ArtryaFeb 15 2024 - Small Caps |
8 |
ResMed Recovery Turns Into Hollywood ScriptJan 31 2024 - Australia |
9 |
ResMed Makes A ComebackJan 29 2024 - Australia |
10 |
ResMed: The Recovery Has BegunJan 23 2024 - Technicals |